Seagen Inc.
Treatment of HER2 positive cancers

Last updated:

Abstract:

In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.

Status:
Grant
Type:

Utility

Filling date:

27 Apr 2018

Issue date:

28 Dec 2021